130 related articles for article (PubMed ID: 36579506)
1. Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients.
Maraia Z; Mazzoni T; Rocchi MBL; Feliciani D; Romani MC; Acciarri G; Rafaiani S; Mazzoni I
J Pers Med; 2022 Oct; 12(11):. PubMed ID: 36579506
[TBL] [Abstract][Full Text] [Related]
2. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
3. Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study.
Belleudi V; Rosa AC; Poggi FR; Armuzzi A; Nicastri E; Goletti D; Diamanti AP; Davoli M; Agabiti N; Addis A
J Clin Med; 2021 May; 10(11):. PubMed ID: 34071452
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
5. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
Liu M; Wang H; Liu L; Cui S; Huo X; Xiao Z; Zhao Y; Wang B; Zhang G; Wang N
Front Immunol; 2022; 13():1046352. PubMed ID: 36389759
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.
Pehlivan Ö; Aydin T
Ann Saudi Med; 2022; 42(3):155-164. PubMed ID: 35658585
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
[TBL] [Abstract][Full Text] [Related]
8. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy.
Conti CB; Mainardi E; Soro S; Testa S; De Silvestri A; Drago A; Cereatti F; Grassia R
World J Gastrointest Endosc; 2022 Mar; 14(3):153-162. PubMed ID: 35432745
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.
Widdifield J; Kwong JC; Chen S; Eder L; Benchimol EI; Kaplan GG; Hitchon C; Aviña-Zubieta JA; Lacaille D; Chung H; Bernatsky S
Lancet Rheumatol; 2022 Jun; 4(6):e430-e440. PubMed ID: 35441151
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
[TBL] [Abstract][Full Text] [Related]
13. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
Raiker R; DeYoung C; Pakhchanian H; Ahmed S; Kavadichanda C; Gupta L; Kardeş S
Semin Arthritis Rheum; 2021 Oct; 51(5):1057-1066. PubMed ID: 34450504
[TBL] [Abstract][Full Text] [Related]
16. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
Brennan-Bourdon LM; De la Cruz-Mosso U; Reyes-Castillo Z; Martínez-Bonilla GE; Ramírez-Dueñas MG; Islas-Carbajal MC; Rincón-Sánchez AR; Salazar-Páramo M; Muñoz-Valle JF
Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
[TBL] [Abstract][Full Text] [Related]
17. Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients.
Waggershauser CH; Tillack-Schreiber C; Weyh P; Alt E; Siegmund T; Berchthold-Benchieb C; Szokodi D; Schnitzler F; Ochsenkühn T
Can J Gastroenterol Hepatol; 2022; 2022():3469789. PubMed ID: 36060521
[TBL] [Abstract][Full Text] [Related]
18. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
19. Biological agents in rheumatoid arthritis: which ones could be used in combination?
Lorenz M; Kalden JR
BioDrugs; 1998 Apr; 9(4):303-24. PubMed ID: 18020567
[TBL] [Abstract][Full Text] [Related]
20. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
